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OBJECTIVE — Proteinuriaisthehallmarkofdiabeticnephropathy;yet,glomerularhistology
does not fully explain mechanisms contributing to proteinuria. Our objective was to identify
proteins in the urine of individuals with type 1 diabetes and microalbuminuria that might
implicate a mechanistic pathway operative in proteinuria.
RESEARCH DESIGN AND METHODS — Using a GeLC/MS platform proteomics ap-
proach, we compared the urine proteome from 12 healthy nondiabetic individuals, 12 subjects
with type 1 diabetes yet normal urinary albumin excretion rates, and 12 subjects with type 1
diabetes and microalbuminuria (type 1 diabetes  microalbuminuria).
RESULTS — The abundance of megalin and cubilin, two multiligand receptors expressed in
kidney proximal tubule cells and involved with the reuptake of ﬁltered albumin and megalin/
cubilin ligands, was signiﬁcantly increased in type 1 diabetes  microalbuminuria urine, com-
pared with both nonalbuminuric groups.
CONCLUSIONS — Aberrant shedding of megalin and cubilin could contribute to albumin-
uria in diabetes and to deﬁciency states of important vitamins and hormones.
Diabetes Care 32:1266–1268, 2009
E
xcess urinary albumin excretion
(UAE) (30–299 mg/day), termed
microalbuminuria, portends incipi-
ent diabetic nephropathy. Mechanisms
contributingtoproteinuriaindiabeticne-
phropathy are incompletely understood
but likely involve pathology within the
glomerulus, including endothelial cell in-
jury, glomerular basement membrane
thickening, loss of slit diaphragm verac-
ity, and podocytopenia (1). Additionally,
in the proximal tubule (PT), decreased
protein reabsorption likely occurs (1,2);
data from diabetic animals suggest that
alteredPThandlinganddiminishedalbu-
min retrieval contribute to albuminuria
(3,4). Because 70% of the urinary pro-
teome originates from kidney or genito-
urinary tissues (5,6), we used the
GeLC/MS platform proteomics approach
to compare the urine proteome from 1)
nondiabetic individuals, 2) subjects with
type 1 diabetes yet normal UAE, and 3)
subjects with type 1 diabetes and mi-
croalbuminuria (type 1 diabetes  mi-
croalbuminuria),soastoidentifyproteins
that might implicate a mechanistic path-
way operative in proteinuria.
RESEARCH DESIGN AND
METHODS— This study was con-
ducted as a subanalysis of a study de-
scribedelsewhere(7);12of143originally
described subjects had type 1 diabetes 
microalbuminuria (UAE 30 mg albu-
min/g creatinine, herein designated as
group 3). Two additional subgroups
(matched to group 3 for age and sex) were
identiﬁed and designated group 1: healthy,
nondiabetic,nonalbuminuricsubjects(n
12); and group 2: subjects with type 1 dia-
betes and normal UAE (30 mg albumin/g
creatinine; n  12). Group characteristics
are available in Table A1 in an online-only
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-0112/DC1.
An SDS-PAGE to liquid chromatogra-
phy–tandem mass spectrometry (GeLC/
MS) platform was used to compare 24-h
urine samples from subjects in groups 1–3.
liquidchromatography–tandemmassspec-
trometry allows for identiﬁcation of pro-
teins in urine; relative protein abundance
was quantiﬁed by spectral counting (5,8).
For each subject, a urine aliquot corre-
sponding to 1,000 g urine creatinine was
calculated.Withineachgroup,these12ali-
quots were pooled into four pools (two fe-
male  two male pools of three subjects
each); each pool was independently ana-
lyzed. ANOVA was used to ascertain differ-
ences between groups. Linear relationships
betweendatawereanalyzedusingthePear-
son product moment correlation.
RESULTS— Groups1–3werecompa-
rable for sex, age, BMI, blood pressure,
andglomerularﬁltrationrate(TableA1in
the online appendix). Groups 2 and 3
werecomparablefordiseasedurationand
displayed higher A1C and continuous
glucose monitoring system glucose and
lower C-peptide values compared with
controls. Per study design, group 3 alone
exhibited increased UAE.
Over 150 protein signatures were
identiﬁed by GeLC/MS analysis to be ei-
ther 1) only identiﬁed in group 3 urine or
2) present in groups 1 and 3 urine but
exhibiting at least two times greater fre-
quency, by spectral counting, in group 3
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most abundant proteins in all groups
were albumin, uromodulin, and -1-
microglobulin/bikunin precursor, re-
spectively. Two PT endocytic receptors,
megalin (i.e., LRP2) and cubilin, active in
the reuptake of ﬁltered small-molecular-
weight proteins (9), were among the 20
most abundant proteins in group 3 urine
(seeTableA2intheonlineappendix)and
weresigniﬁcantlymoreabundantinurine
fromgroup3,comparedwithgroups1or
2 (Table 1). Neither receptor was identi-
ﬁed in the 20 most abundant proteins in
groups 1 or 2. Megalin and cubilin form a
complexonthecellsurfaceofPTcells(9).
Using data from all groups, megalin and
cubilin mean spectral counts were highly
correlated, consistent with evidence that
they form a cellular complex and are co-
excreted in urine (Table 1).
Megalin is a membrane-bound pro-
tein, and the extracellular domain can be
shed from PT cells (10). Analysis of the
peptide spectra generated by GeLC/MS
revealedthat99%ofthepeptideﬁnger-
printing covered regions of the extracel-
lular domain. Moreover, the most
COOH-terminal peptide detected in all
groups extended to amino acid 4304
within the extracellular domain, suggest-
ing that urinary megalin represents pre-
dominantly the extracellular component.
Megalin and cubilin participate in the
reuptake and endocytosis by PT cells of a
number of proteins including albumin.
Several megalin and/or cubilin ligands
were elevated in or only detected in urine
from group 3 (Table 1). Analyzing data
fromallgroups,theurinaryabundanceof
albumin correlated with the urinary
abundance of both megalin and cubilin
(Table 1). Several other megalin/cubilin
ligands also correlated with megalin/
cubilin abundance (Table 1).
CONCLUSIONS — Megalin is an
600-kDa single-spanning transmem-
brane glycoprotein belonging to the LDL
receptor family (9). This endocytic recep-
torisprimarilyexpressedinpolarizedep-
ithelial cells including PT cells of the
kidney and is a multiligand receptor with
many ligands including albumin, vita-
min-binding proteins, carrier proteins, li-
poproteins, hormones, and drugs (9).
Cubilinisan460-kDaperipheralmem-
brane glycoprotein with no transmem-
brane component (9). Also expressed in
renal PT cells, cubilin binds several li-
gandsincommonwithmegalinincluding
albumin, vitamin D binding protein,
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gether, these receptors are responsible for
the tubular clearance of most ﬁltered pro-
teins. In fact, over 95% of ﬁltered albu-
min is reabsorbed in the PT primarily via
the megalin-cubilin complex (2). Because
megalin and cubilin are involved in re-
uptake of albumin and smaller proteins
from the glomerular ﬁltrate, diminished
functioning of these receptors in diabetes
could contribute to proteinuria. Animal
and clinical investigations support this
hypothesis by demonstrating selective
proteinuria in conditions of megalin or
cubilin loss of function (11–13).
Studies have shown that LRP family
members, including megalin, are shed
from cell surfaces by matrix metallopro-
teinases (10). Matrix metalloproteinase
activityiselevatedintype1diabetesurine
(7), and matrix metalloproteinase expres-
sion is altered in the diabetic kidney (14).
Thus,enhancedmatrixmetalloproteinase
activityintheparenchymaand/ortubular
lumen of the diabetic kidney might result
in shedding of the megalin/cubilin com-
plex from PT cell surfaces. Secondary to
megalin and cubilin loss, isolated deﬁ-
ciencies of certain small-molecular-
weight proteins and their ligands (i.e.,
vitamins) would be predicted.
Certain study limitations exist. This
study was a sub-analysis of a preexisting
dataset and was not intended to predict
disease progression, but, rather, to iden-
tify proteins that might infer a mechanis-
tic pathway operative in diabetic
nephropathy. Conﬁrmation that “mega-
lin-uria” or “cubilin-uria” correlates with
orpredictsmicroalbuminuriawillrequire
measurement of megalin and cubilin in
individual specimens from a larger pro-
spective cohort. At present, however,
there are no immunometric assays for
megalin or cubilin to allow for quantita-
tive assessment.
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